-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NM+rd0BCM+vKZ6yp4gC4V/RnS4VjQvC9V8AX06+KKMUK78592suGpdoebUggC0dM wrF/mph+NcEW5Sgc7rYwaQ== 0000950123-05-014749.txt : 20051214 0000950123-05-014749.hdr.sgml : 20051214 20051214170845 ACCESSION NUMBER: 0000950123-05-014749 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051214 ITEM INFORMATION: Other Events FILED AS OF DATE: 20051214 DATE AS OF CHANGE: 20051214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1204 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 051264534 BUSINESS ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 8-K 1 y15620ae8vk.htm FORM 8-K FORM 8-K
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2005
OSI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation) 		  0-15190
(Commission
File Number) 		  13-3159796
(I.R.S. Employer
Identification No.)
58 South Service Road
Melville, NY 11747
(Address of principal executive offices)
(631) 962-2000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a- 12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
 
 

 

TABLE OF CONTENTS

ITEM 8.01. Other Events
SIGNATURE

Table of Contents

ITEM 8.01. Other Events
     In the proxy statement for our 2005 Annual Meeting of Stockholders, we stated that because we changed our fiscal year end from September 30 to December 31, our 2006 Annual Meeting would be postponed from March 2006, the month during which we would traditionally hold our annual meeting. We have today set June 14, 2006 as the date of the 2006 Annual Meeting, and accordingly we are in a position to advise stockholders of the deadlines applicable for the submission of proposals for such meeting.
     Stockholders who intend to submit proposals to be included in our Proxy Statement for the Annual Meeting of Stockholders to be held on June 14, 2006 must submit their proposals to the Secretary of the Corporation at 58 South Service Road, Suite 110, Melville, New York 11747, not later than January 31, 2006. Such proposals must relate to matters appropriate for stockholder action and be consistent with regulations of the SEC.
     Stockholders who intend to present proposals at our 2006 Annual Meeting, not intending to have such proposals included in the Proxy Statement for that meeting, must submit their proposal to the Secretary of the Corporation at 58 South Service Road, Suite 110, Melville, New York 11747, not later than March 16, 2005. If notification of a stockholder proposal is not received by the above date, the proposal may not be presented.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: December 14, 2005   OSI PHARMACEUTICALS, INC.
 		  
  By:   /s/ BARBARA A. WOOD    
    Barbara A. Wood   
    Vice President, General Counsel and
Secretary 		  
 

 

-----END PRIVACY-ENHANCED MESSAGE-----